← Leaderboards
Konrad Talbot
University Of California Los Angeles
$1,868,086
Attributed
$3,736,172
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $938.5K · FY2018–22$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,736,172 · 1
By mechanism
R01$3,736,172 · 1
Top collaborators
- Gregory M Cole7 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Zhengping Yi$6,465,921
- Willa A. Hsueh$20,743,184
- Paul M Thompson$55,589,208
- Sanjiv S Gambhir$44,452,033
- James A Waschek$5,026,715
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposAcuteBrain PathologyAmyloid Beta-ProteinAgonistAnimal ModelAnimalsAntidiabetic DrugsApp-Ps1AreaAnimal Disease ModelsBlood - Brain Barrier AnatomyBlood VesselsBrainAffectBrain TissueCerebrumChronicClinical Trials DesignCognitionCognitive DeficitsCytokineBaseDiabetes Mellitus
Grant awards (7)
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists$684,076
R01 · FY2022 · AG · contact PI
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists$684,515
R01 · FY2021 · AG · contact PI
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists$690,558
R01 · FY2020 · AG · contact PI
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists$193,430
R01 · FY2020 · AG · contact PI
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists$54,500
R01 · FY2020 · AG · contact PI
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists$746,208
R01 · FY2019 · AG · contact PI
Treating Alzheimer's disease by reducing brain insulin resistance with incretin receptor agonists$682,885
R01 · FY2018 · AG · contact PI